Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-Amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

British Journal of Cancer

Volumn 115, Issue 3, 2016, Pages 303-311

  Cocco, Emiliano ^a   Lopez, Salvatore ^b   Black, Jonathan ^a   Bellone, Stefania ^a   Bonazzoli, Elena ^a   Predolini, Federica ^a   Ferrari, Francesca ^a   Schwab, Carlton L ^a   Menderes, Gulden ^a   Zammataro, Luca ^a   Buza, Natalia ^a   Hui, Pei ^a   Wong, Serena ^a   Zhao, Siming ^a   Bai, Yalai ^a   Rimm, David L ^a   Ratner, Elena ^a   Litkouhi, Babak ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Santin, Alessandro D ^a   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

CCNE1; CDK2; CDK9; PIK3CA; uterine serous carcinoma

Indexed keywords

CYC 065; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE 9; CYCLIN E1; CYCLINE; TASELISIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CCNE1 PROTEIN, HUMAN; CYCLIN E; MESSENGER RNA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ASSAY; CELL CYCLE G1 PHASE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TISSUE MICROARRAY; TUMOR XENOGRAFT; UTERUS CARCINOMA; ANIMAL; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SILENCING; GENETICS; METABOLISM; MUTATION; TUMOR CELL LINE; UTERINE NEOPLASMS; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLIN E; DNA COPY NUMBER VARIATIONS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; IN VITRO TECHNIQUES; MICE; MUTATION; ONCOGENE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; UTERINE NEOPLASMS;

EID: 84976350838     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.198     Document Type: Article

References (43)

1. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. (2015). The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14(2): 130-146
2. Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P. (2015). FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 21(21): 4760-4766
3. Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. (2015). PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. Br J Cancer 113(11): 1641
4. Bose P, Simmons GL, Grant S. (2013). Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Invest Drugs 22(6): 723-738
5. Cancer Genome Atlas Network. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490(7418): 61-70
6. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. (2013). Integrated genomic characterization of endometrial carcinoma. Nature 497(7447): 67-73
7. Chou TC. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3): 621-681
8. Ekholm SV, Reed SI. (2000). Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12(6): 676-684
9. Engelman JA, Janne PA. (2008). Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10): 2895-2899
10. English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T, Santin AD. (2013). Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol 209(5): 465 e1-465 e9
11. Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD. (2013). Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-Amplified ovarian cancer. Clin Cancer Res 19(21): 5960-5971
12. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M. Australian Ovarian Cancer Study GGorringe KL, Smyth GK, Bowtell DD. (2010). Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 5(11): e15498
13. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE. (1994). Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54(3): 264-268
14. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. (2008). A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclindependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26(1): 59-65
15. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. (1982). Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6(2): 93-108
16. Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Muller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH, Reed SI, Widschwendter M. (2004). Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene 23(23): 4187-4192
17. Kuhn E, Bahadirli-Talbott A, Shih Ie M. (2014). Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol 27(7): 1014-1019
18. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih Ie M. (2012). Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 104(19): 1503-1513
19. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella-Borradori A, Dieras V, Raymond E. (2010). Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclindependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 46(18): 3243-3250
20. Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD. (2015). Dual HER2/PIK3CA targeting overcomes single-Agent acquired resistance in HER2-Amplified uterine serous carcinoma cell lines in vitro and in vivo. Mol Cancer Ther 14(11): 2519-2526
21. Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD. (2014). Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol 135(2): 312-317
22. Lundgren C, Ahlin C, Holmberg L, Amini RM, Fjallskog ML, Blomqvist C. (2015). Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study. Acta Oncol 54(4): 538-544
23. Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT, Harper JW. (2000). Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 14(18): 2298-2313
24. MacKay C, Frame S, Saladino C, Pohler E, Zheleva D, Blake DG. (2015). Abstract B182: Molecular basis for clinical development of the novel CDK2/9 inhibitor CYC065 in oncology. Mol Cancer Ther 14: B182
25. Moore KN, Fader AN. (2011). Uterine papillary serous carcinoma. Clin Obstet Gynecol 54(2): 278-291
26. Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, Jou YM, Statkevich P, Yao SL, Bannerji R. (2013). A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 11: 259
27. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K. (2000). Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103(1): 127-140
28. Reed SI. (1996). Cyclin E: in mid-cycle. Biochim Biophys Acta 1287(2-3): 151-153
29. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J. (2006). Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106(9): 1925-1932
30. Saladino C, Frame S, Davis S, Blake D, Zheleva D. (2015). Abstract 1650: CYC065, a novel CDK2/5/9 inhibitor: detailed mechanistic studies, determinants of sensitivity and synergistic combinations. Cancer Res 75: 1650-1650
31. Scaltriti M, Eichhorn PJ, Cortes J, Prudkin L, Aura C, Jimenez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzman M, Gili M, Rodriguez O, Rodriguez S, Perez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. (2011). Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2± breast cancer patients. Proc Natl Acad Sci USA 108(9): 3761-3766
32. Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD. (2014). Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol 135(1): 142-148
33. Schwab CL, Santin AD. (2015). Targeted therapy in the treatment of uterine serous carcinoma. Pharmacogenomics 16(2): 97-99
34. Schwartz PE. (2006). The management of serous papillary uterine cancer Curr Opin Oncol 18 5 494-499
35. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA. (1998). Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16(9): 2986-2999
36. Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE, Knudsen ES. (2001). Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Mol Cell Biol 21(12): 4032-4045
37. Shapiro GI. (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24(11): 1770-1783
38. Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015. CA Cancer J Clin 65(1): 5-29
39. Sui L, Dong Y, Ohno M, Sugimoto K, Tai Y, Hando T, Tokuda M. (2001). Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 83(1): 56-63
40. Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR. (2015). Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget 6(2): 696-714
41. Whittaker SR, Walton MI, Garrett MD, Workman P. (2004). The cyclindependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-Activated protein kinase pathway. Cancer Res 64(1): 262-272
42. Yang L, Fang D, Chen H, Lu Y, Dong Z, Ding HF, Jing Q, Su SB, Huang S. (2015). Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. Oncotarget 6(25): 20801-20812
43. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. (2013). Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA 110(8): 2916-2921